EP1692176A4 - Anti-igf-i receptor antibody - Google Patents

Anti-igf-i receptor antibody

Info

Publication number: EP1692176A4
Authority: EP; European Patent Office
Prior art keywords: igf; receptor antibody; antibody; receptor
Prior art date: 2003-12-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP04811082A

Other languages

German (de)

French (fr)

Other versions

EP1692176A1 (en

Inventor

Rajeeva Singh

Daniel J Tavares

Nancy E Dagdigian

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunogen Inc

Original Assignee

Immunogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-08

Filing date

2004-12-07

Publication date

2008-11-12

2003-12-08 Priority claimed from US10/729,441 external-priority patent/US8034904B2/en

2004-12-07 Application filed by Immunogen Inc filed Critical Immunogen Inc

2006-08-23 Publication of EP1692176A1 publication Critical patent/EP1692176A1/en

2008-11-12 Publication of EP1692176A4 publication Critical patent/EP1692176A4/en

Status Ceased legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP04811082A 2003-12-08 2004-12-07 Anti-igf-i receptor antibody Ceased EP1692176A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/729,441 US8034904B2 (en)	2002-06-14	2003-12-08	Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en)	2002-06-14	2004-12-07	Anti-igf-i receptor antibody

Publications (2)

Publication Number	Publication Date
EP1692176A1 EP1692176A1 (en)	2006-08-23
EP1692176A4 true EP1692176A4 (en)	2008-11-12

Family

ID=36616549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04811082A Ceased EP1692176A4 (en)	2003-12-08	2004-12-07	Anti-igf-i receptor antibody

Country Status (13)

Country	Link
EP (1)	EP1692176A4 (en)
JP (1)	JP2008502589A (en)
KR (1)	KR20070001883A (en)
CN (1)	CN1886424A (en)
AU (1)	AU2004303792A1 (en)
BR (1)	BRPI0417406A (en)
CA (1)	CA2548065A1 (en)
CR (1)	CR8426A (en)
EA (1)	EA009807B1 (en)
EC (1)	ECSP066595A (en)
IL (1)	IL174770A0 (en)
MX (1)	MXPA06005540A (en)
NO (1)	NO20063155L (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201636048A (en)	2009-12-21	2016-10-16	建南德克公司	Antibody formulation
MX2012013068A (en) *	2010-05-11	2013-03-05	Aveo Pharmaceuticals Inc	Anti-fgfr2 antibodies.
EP2766478A4 (en)	2011-10-10	2015-06-17	Los Angeles Childrens Hospital	Novel asparaginase and methods for treating diseases associated with asparagine dependence
CN103509117B (en) *	2013-05-06	2016-03-09	江苏匡亚生物医药科技有限公司	Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
JP6987136B2 (en) *	2017-05-30	2021-12-22	帝人ファーマ株式会社	Anti-IGF-I receptor antibody
CN118615438A (en) *	2023-03-07	2024-09-10	康方药业有限公司	Pharmaceutical combination comprising anti-CTLA 4-anti-PD-1 bispecific antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002053596A2 (en) *	2001-01-05	2002-07-11	Pfizer Inc.	Antibodies to insulin-like growth factor i receptor
WO2003106621A2 (en) *	2002-06-14	2003-12-24	Immunogen, Inc.	Anti-igf-i receptor antibody
WO2004071529A2 (en) *	2003-02-13	2004-08-26	Pfizer Products Inc.	Uses of anti-insulin-like growth factor i receptor antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000034780A2 (en) *	1998-12-04	2000-06-15	Novartis Ag	METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?

2004
- 2004-12-07 JP JP2006543832A patent/JP2008502589A/en active Pending
- 2004-12-07 CA CA002548065A patent/CA2548065A1/en not_active Abandoned
- 2004-12-07 EP EP04811082A patent/EP1692176A4/en not_active Ceased
- 2004-12-07 KR KR1020067010010A patent/KR20070001883A/en not_active Application Discontinuation
- 2004-12-07 CN CNA200480034889XA patent/CN1886424A/en active Pending
- 2004-12-07 MX MXPA06005540A patent/MXPA06005540A/en active IP Right Grant
- 2004-12-07 BR BRPI0417406-2A patent/BRPI0417406A/en not_active IP Right Cessation
- 2004-12-07 EA EA200600931A patent/EA009807B1/en not_active IP Right Cessation
- 2004-12-07 AU AU2004303792A patent/AU2004303792A1/en not_active Abandoned
2006
- 2006-04-04 IL IL174770A patent/IL174770A0/en unknown
- 2006-05-31 EC EC2006006595A patent/ECSP066595A/en unknown
- 2006-06-01 CR CR8426A patent/CR8426A/en not_active Application Discontinuation
- 2006-07-07 NO NO20063155A patent/NO20063155L/en not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002053596A2 (en) *	2001-01-05	2002-07-11	Pfizer Inc.	Antibodies to insulin-like growth factor i receptor
WO2003106621A2 (en) *	2002-06-14	2003-12-24	Immunogen, Inc.	Anti-igf-i receptor antibody
WO2004071529A2 (en) *	2003-02-13	2004-08-26	Pfizer Products Inc.	Uses of anti-insulin-like growth factor i receptor antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
See also references of WO2005061541A1 *
SURMACZ E: "Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor", ONCOGENE, NATURE PUBLISHING GROUP, GB BASINGSTOKE, HANTS, vol. 22, no. 42, 29 September 2003 (2003-09-29), pages 6589 - 6597, XP002392351, ISSN: 0950-9232 *

Also Published As

Publication number	Publication date
NO20063155L (en)	2006-08-11
AU2004303792A1 (en)	2005-07-07
BRPI0417406A (en)	2007-04-03
CA2548065A1 (en)	2005-07-07
KR20070001883A (en)	2007-01-04
MXPA06005540A (en)	2006-08-17
CN1886424A (en)	2006-12-27
EP1692176A1 (en)	2006-08-23
IL174770A0 (en)	2006-08-20
EA200600931A1 (en)	2006-10-27
JP2008502589A (en)	2008-01-31
EA009807B1 (en)	2008-04-28
ECSP066595A (en)	2006-10-17
CR8426A (en)	2007-12-04

Legal Events

Date	Code	Title	Description
2006-07-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-08-23	17P	Request for examination filed	Effective date: 20060612
2006-08-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2006-08-23	AX	Request for extension of the european patent	Extension state: BA HR LV MK YU
2006-08-30	RAX	Requested extension states of the european patent have changed	Extension state: YU Payment date: 20060612 Extension state: MK Payment date: 20060612 Extension state: LV Payment date: 20060612 Extension state: HR Payment date: 20060612 Extension state: BA Payment date: 20060612 Extension state: AL Payment date: 20060612
2008-11-12	A4	Supplementary search report drawn up and despatched	Effective date: 20081010
2008-11-12	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101ALI20081006BHEP Ipc: C07K 16/28 20060101ALI20081006BHEP Ipc: C12N 15/00 20060101ALI20081006BHEP Ipc: C07H 21/04 20060101ALI20081006BHEP Ipc: C07K 16/00 20060101AFI20050708BHEP
2009-06-17	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: IMMUNOGEN, INC.
2010-03-17	17Q	First examination report despatched	Effective date: 20100211
2012-07-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2012-12-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2013-01-23	18R	Application refused	Effective date: 20120719

Publication	Publication Date	Title
IL175710A0 (en)	2006-09-05	Anti-mpl antibody
PT1599504E (en)	2015-03-02	Modified antibody
IL175608A0 (en)	2006-09-05	Antibodies
EP1494693A4 (en)	2006-08-02	Cripto-specific antibodies
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
IL228033A0 (en)	2013-09-30	Antibodies
IL172822A0 (en)	2006-06-11	Muscarnic acetylcholine receptor antagonists
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
AU2003257032A8 (en)	2004-02-23	Antibodies against c3a receptor
ZA200701952B (en)	2008-10-29	Anti-OX40L antibodies
IL173337A0 (en)	2006-06-11	Receptor
EP1692176A4 (en)	2008-11-12	Anti-igf-i receptor antibody
IL163580A0 (en)	2005-12-18	Assay for anti-ingap antibodies
EP1696949A4 (en)	2008-02-06	Vegf receptor antagonists
EP1780221A4 (en)	2007-10-03	Anti-synoviolin antibody
GB0306618D0 (en)	2003-04-30	Antibody
GB0226878D0 (en)	2002-12-24	Antibodies
GB0414798D0 (en)	2004-08-04	Receptor
GB0306428D0 (en)	2003-04-23	Receptor proteins
GB0215389D0 (en)	2002-08-14	Receptor
GB0321998D0 (en)	2003-10-22	Receptor
GB0418415D0 (en)	2004-09-22	Antibody
HK1209139A1 (en)	2016-03-24	Modified antibody
GB0307100D0 (en)	2003-04-30	Receptor
GB0329104D0 (en)	2004-01-21	Receptor